Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in lymphoma
- Trial result
Lymphoma
Glofitamab (CD20xCD3) + polatuzumab vedotin (CD79b ADC) blunts high-risk biology signals in R/R LBCL biomarker analysis
Glofitamab is a CD20xCD3 T-cell–engaging bispecific antibody and polatuzumab vedotin is a CD79b-directed ADC (MMAE payload); this exploratory analysis compared tumor RNAseq and peripheral T-cell pharmacodynamics for…
NCT03533283 - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) Delivers 38% 5-Year OS in R/R LBCL, Supporting a “Plateau”
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T cell therapy evaluated in the Phase 1 TRANSCEND NHL 001 program in relapsed/refractory large B-cell lymphoma (R/R LBCL) after ≥2 prior lines.…
NCT02631044 - New trial
Lymphoma
Phase 2 epcoritamab CD3×CD20 bispecific T‑cell engager plus DA‑EPOCH‑R in high‑risk Burkitt lymphoma
This Phase 2 BEDROCK study tests whether adding epcoritamab (Epkinly; a subcutaneous CD3×CD20 bispecific antibody that redirects T cells to kill CD20+ B‑cell lymphoma) can improve outcomes when layered onto…
NCT07662928 Exploratory - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) delivers 88% ORR/80% CR in real-world R/R mantle cell lymphoma
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T product with a defined CD4:CD8 composition and 4-1BB costimulation, evaluated here in a US CIBMTR retrospective real-world cohort of commercial…
- Trial result Spotlight
Lymphoma
Golcadomide (CC-99282) CELMoD + rituximab drives 97% ORR/78% CR in heavily pretreated R/R follicular lymphoma
Golcadomide (GOLCA; CC-99282) is an oral cereblon E3 ligase modulator (CELMoD) that degrades Ikaros/Aiolos to combine direct tumor cell killing with immunomodulatory effects; in the Phase 1/2 CC-99282-NHL-001 study…
NCT03930953 - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) Drives 89% ctDNA-MRD Negativity in 3L+ R/R Follicular Lymphoma, Tracking with 36-mo PFS
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T cell therapy; in this exploratory TRANSCEND FL (NCT04245839) analysis of third-line or later (3L+) relapsed/refractory follicular lymphoma,…
NCT04245839 - Trial result
Lymphoma
EPCORE NHL-6: SC epcoritamab (CD3×CD20) enables outpatient R/R DLBCL dosing with 64% ORR and 27.2-mo mOS
Epcoritamab is a subcutaneous CD3×CD20 bispecific T-cell engager (already approved in the US for R/R DLBCL) evaluated in the Phase 2 EPCORE NHL-6 outpatient-feasibility study in 2L+ R/R DLBCL across US/Puerto Rico…
NCT05451810 - Trial result
Lymphoma
Epcoritamab (CD20×CD3 bispecific) + R-miniCVP posts 86% CR in frail/anthracycline-ineligible newly diagnosed DLBCL
Epcoritamab is a subcutaneous CD20×CD3 T-cell–engaging bispecific antibody combined here with rituximab–miniCVP (cyclophosphamide/vincristine/prednisone; no anthracycline) in an open-label, single-arm Phase 2 MD…
NCT06045247 - Trial result
Lymphoma
Odronextamab (CD20xCD3 bispecific) + CHOP drives 85% CR in high-risk, untreated DLBCL (OLYMPIA-3 Part 1B)
Odronextamab is an off-the-shelf CD20xCD3 T-cell–engaging bispecific antibody combined here with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) as first-line therapy in untreated CD20+ DLBCL or high-grade…
NCT06091865 - Trial result
Lymphoma
AZD3470 (MTA-cooperative PRMT5 inhibitor) hits 80% ORR/50% CR in MTAP-deficient r/r cHL (Phase 1)
AZD3470 is an oral, MTA-cooperative PRMT5 inhibitor designed to preferentially engage PRMT5 in MTAP-deficient tumor cells; in this first-in-human Phase 1 PRIMAVERA dose-escalation study (NCT06137144), adults with…
NCT06137144 - New trial
Lymphoma
Phase 2 dexrazoxane Top2β cardioprotectant vs liposomal doxorubicin anthracycline in DLBCL
This Phase 2 randomized, double-blind, double-dummy CARDIOPROTECT trial tests two strategies to reduce anthracycline-related heart failure events in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients at…
NCT07654426 Exploratory - New trial
Lymphoma
Phase 1 axatilimab CSF1R-blocking monoclonal antibody conditions macrophages alongside commercial CAR-T.
This open-label Phase 1 study (“MAC-SHIFT”) at Northside Hospital evaluates whether adding axatilimab—a CSF1R-directed monoclonal antibody that inhibits macrophage/monocyte CSF-1R signaling and can reduce…
NCT07638982 Exploratory - New trial
Lymphoma
Phase 1 huCART19-IL18-eDHFR CD19 CAR-T secreting IL-18 with PET cell-tracking
This Phase 1, open-label, single-arm study from the University of Pennsylvania tests huCART19-IL18-eDHFR: an autologous, CD19-directed CAR T-cell therapy “armored” to secrete interleukin‑18 (IL‑18) to boost antitumor…
NCT07343934 First-in-human - New trial Spotlight
Lymphoma
Phase 1 CART-45 anti-CD45 CAR T + CD45 base-edited HSPC epitope shield
University of Pennsylvania’s Phase 1 open-label, dose-finding study evaluates a two-step, autologous cell-therapy strategy: infusion of CD45 base-edited hematopoietic stem and progenitor cells (CD45BE-HSPC) followed…
NCT07451054 First-in-human - New trial
Lymphoma
Phase 1/2 golcadomide (CELMoD cereblon E3 ligase modulator) + rituximab (CD20 mAb) in R/R MCL
This Phase 1/2 City of Hope trial evaluates golcadomide plus rituximab for relapsed/refractory mantle cell lymphoma in patients resistant or intolerant to covalent BTK inhibitors. Golcadomide (CC-99282; a Bristol…
NCT07578077 Exploratory - New trial
Lymphoma
Phase 2 nemtabrutinib non-covalent BTK inhibitor plus rituximab anti-CD20 mAb in MZL
City of Hope is running this Phase 2, open-label combination study testing nemtabrutinib + rituximab in patients with marginal zone lymphoma (MZL) who have radiographically measurable nodal or extranodal disease.…
NCT07583810 Exploratory - New trial Spotlight
Lymphoma
Phase 3 PTCL-STAT tests high-dose chemotherapy (DNA-damaging cytotoxic conditioning) + autologous stem cells
This randomized Phase 3 ECOG-ACRIN study (PTCL-STAT; EA4232) asks whether consolidative high-dose chemotherapy followed by autologous stem cell transplant (ASCT) improves outcomes versus observation alone for…
NCT06724237 Registrational - New trial
Lymphoma
Phase 2 epcoritamab CD20×CD3 bispecific antibody plus R-CHOP in newly diagnosed aggressive B-cell NHL
This Phase 2, open-label, two-arm, sequential-assignment study tests epcoritamab (a subcutaneous CD20×CD3 T-cell–engaging bispecific antibody) combined with R-CHOP in newly diagnosed, CD20+ aggressive B-cell…
NCT07588698 Exploratory - New trial
Lymphoma
Phase 2 emapalumab IFN-γ–neutralizing antibody to prevent BsAb CRS/ICANS in R/R MM, LBCL
This Phase 2, single-arm prophylaxis study tests whether emapalumab (Gamifant)—an interferon-gamma (IFN-γ)–blocking monoclonal antibody—can reduce cytokine release syndrome (CRS) and/or immune effector…
NCT07567014 Exploratory - Trial result Spotlight
Lymphoma
Pirtobrutinib (non-covalent BTK inhibitor) drives 82.5% ORR in R/R Waldenström’s at ~3-year follow-up
Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor evaluated as monotherapy in the open-label, multicentre Phase 1/2 BRUIN trial (NCT03740529) in relapsed/refractory…
NCT03740529 - New trial
Lymphoma
Phase 2 nivolumab PD-1 checkpoint inhibitor plus AVD chemo in early-stage pediatric cHL
This MD Anderson–sponsored Phase 2, open-label, single-arm study evaluates nivolumab (Bristol Myers Squibb; PD-1/CD279–blocking monoclonal antibody that reinvigorates anti-tumor T cells) combined with AVD…
NCT07551583 Exploratory - New trial
Lymphoma
Phase 1 KK2223 in R/R T-cell NHL (PTCL/CTCL)
*No disclosed MOA. We do not include details of trials without this basic information.*
NCT07192471 First-in-human - New trial
Lymphoma
Phase 2 mosunetuzumab CD20×CD3 bispecific antibody + pirtobrutinib noncovalent BTK inhibitor in R/R WM.
University of Utah’s MPOWER is a Phase 2, open-label study testing safety/tolerability and early activity of mosunetuzumab plus pirtobrutinib for relapsed/refractory Waldenström macroglobulinemia after prior covalent…
NCT07548450 Exploratory - New trial
Lymphoma
Phase 2 VG712 anti-CD3 immunotoxin (diphtheria toxin fusion) vs mogamulizumab in MF
Virogen Biotechnology’s CurbMF-001 is a Phase 2, multi-center study in relapsed/refractory mycosis fungoides (stage IB–IVB) after ≥2 prior systemic therapies, with a lead-in dose-finding component (BOIN design; up to…
NCT07529405 Exploratory - New trial
Lymphoma
Phase 1b REBEL tests EBRT then epcoritamab/glofitamab CD20×CD3 T‑cell engagers in R/R DLBCL.
This Phase 1b, single-group, open-label study at University of Utah evaluates whether a short course of external beam radiation therapy (up to ~20 Gy, delivered over 5 days) can be safely followed immediately by a…
NCT07528352 Exploratory - New trial
Lymphoma
Phase 1 pomalidomide (IMiD cereblon modulator) to boost CD19 CAR‑T persistence
This single-center, single-arm Phase 1 pilot at University of Michigan Rogel Cancer Center evaluates whether short-course pomalidomide given after CD19-directed CAR‑T can safely improve CAR‑T expansion/persistence…
NCT07532525 Exploratory - New trial Spotlight
Lymphoma
Phase I MB-CART19.1 (CD19 CAR-T) for CNS lymphoma
MSK identifies the maximum safe dose of on-site–manufactured CD19 CAR-T for primary/secondary CNS lymphoma (incl. DLBCL), using CliniMACS Prodigy (Miltenyi Biomedicine), leukapheresis, conditioning chemo, and…
NCT07137494 Exploratory - Trial result Spotlight
Lymphoma
Haihe’s HH2853 (EZH1/2 dual) achieves 31% ORR, 16-mo mPFS in epithelioid sarcoma
HH2853 is an oral dual EZH1/2 histone-methyltransferase (PRC2) inhibitor; in an open-label, global Phase I dose-escalation/expansion (NCT04390737) across refractory solid tumors and NHL (n=61; 57 evaluable), seven…
NCT04390737 - New trial Spotlight
Lymphoma
Phase II Odronextamab bispecific CD20/CD3 antibody for follicular lymphoma
This Phase II study evaluates odronextamab, a CD20/CD3 bispecific monoclonal antibody, as monotherapy for treatment-naïve follicular lymphoma patients. It uses a multi-cycle dosing design with imaging, ECG, and…
NCT07128641 Exploratory - New trial
Lymphoma
Phase II Study: iC9/CD5CAR/IL-15 NK Cells CD5-targeted immunotherapy
This Phase II trial by MD Anderson explores the safety and efficacy of consolidation therapy using iC9/CD5CAR/IL-15 natural killer cells—engineered to target CD5 on aggressive T-cell lymphomas—in patients in first…
NCT07137481 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.